Commentary Open Access
Volume 2 | Issue 3 | DOI: ttps://doi.org/10.33696/diabetes.1.025
Metformin in Patients with Chronic Heart Failure
Henrik Wiggers1,*, Anders Hostrup Larsen1, Lars Køber2, Gunnar Gislason3, Morten Schou4, Mikael Kjær Poulsen5, Søren Vraa6, Olav Wendelbo Nielsen7, Niels Eske Bruun8, Morten Bøttcher9, Kirsten Vilain Mikkelsen10, Jens Lomholdt11, Søren Lund Kristensen2, Christian Torp-Petersen12, Hans Eiskjær13, Jacob Møller2, Bo Martin Bibby14, Christian Hassager2, Flemming Hald Steffensen15, Jens Refsgaard16, Dan Eik Høfsten2, Søren Mellemkjær13, Finn Gustafsson2, Helene Nørrelund17
- 1Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
- 2Department of Cardiology, Rigshospitalet, Copenhagen, Denmark
- 3The Danish Heart Foundation, Denmark
- 4Department of Cardiology, Herlev Hospital, Denmark
- 5Department of Cardiology, Odense University Hospital, Denmark
- 6Department of Cardiology, Aalborg University Hospital, Denmark
- 7Department of Cardiology, Bispebjerg Hospital, Denmark
- 8Department of Cardiology, Roskilde Hospital, Denmark
- 9Department of Cardiology, Herning Hospital, Denmark
- 10Department of Cardiology, Sydvestjysk Sygehus, Esbjerg, Denmark
- 11Department of Cardiology, Slagelse Hospital, Denmark
- 12Department of Cardiology, Hillerød Hospital, Denmark
- 13Department of Cardiology, Aarhus University Hospital, Denmark
- 14Department of Biostatistics, Aarhus University, Aarhus, Denmark
- 15Department of Cardiology, Lillebaelt Hospital, Vejle, Denmark
- 16Department of Cardiology, Viborg Hospital, Denmark
- 17Clinical Trial Unit, Aarhus University Hospital, Denmark
Corresponding Author
Henrik Wiggers, henrikwiggers@dadlnet.dk
Received Date: November 03, 2020
Accepted Date: December 14, 2020
Wiggers H, Larsen AH, Køber L, Gislason G, Schou M, Poulsen MK, et al. Metformin in Patients with Chronic Heart Failure. J Diabetes Clin Res. 2020; 2(3):100-105.
Copyright: © 2020 Wiggers H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
Heart failure, Metformin, Diabetes, Insulin resistance, Obesity, Randomized trial
Recommended Articles
Prospective Evaluation of Effect of Metformin on Activation of AMP-activated Protein Kinase (AMPK) and Disease Control in a Sub-group Analysis of Patients with GI Malignancies
Observational studies have demonstrated association of metformin with reduced cancer incidence and mortality in multiple cancer types, including gastrointestinal (GI) malignancies. Anti-neoplastic effects of metformin are believed through many mechanisms including activation of AMP-activated protein kinase, which controls mammalian target of rapamycin (mTOR) growth regulatory pathway.
Platelet Hyperactivity and Dysfunction in Diabetes and Cancer
However, the entire coagulation cascade is dysfunctional, in progressed chronic diabetes and cancer patients.
How Traditional Healers Diagnose and Treat Diabetes Mellitus in the Pretoria Mamelodi Area and How Do These Purported Medications Comply with Complementary and Alternative Medicine Regulations
CAM is widely used by patients to treat and prevent certain diseases, providing emotional and physical support [1]. The National Centre for Complementary and Alternative Medicine (NCCAM) defines CAM as a “group of diverse medical and health care systems, practices, and products that are not presently considered to be part of conventional medicine” [2].
Energy Expenditure and Nutrition in Neurogenic Obesity following Spinal Cord Injury
Worldwide, obesity is a public health concern and a metabolic ailment characterized by excessive adipose tissue accumulation resulting from an imbalance of energy expenditure and energy intake [1]. This disorder is a known risk factor for cardiovascular disease, type 2 diabetes mellitus, dyslipidemia, hypertension, and metabolic
The Link of Nutrient Fluxes to Hepatic Insulin Resistance at Gene Expression
Insulin resistance has been studied extensively at systemic, organ, tissue and cellular and molecular levels. Overnutrition plays an essential role in the development of chronic metabolic diseases such as obesity and type 2 diabetes. For subjects without genetic defects, the development of insulin resistance and type 2 diabetes is a graduate process. How the transition from an insulinsensitive state to an insulin-resistant state occurs, and what the roles of nutrients are in the process have not been fully understood. Here, we try to summarize the current understanding of insulin-regulate gene expression in the liver, and describe a phenomenon of hepatic insulin resistance at gene expression (HIRAGE), which may be linked to overnutrition.